Omnicell reported a strong fourth quarter and full year 2020, exceeding expectations and achieving record product bookings of over $1 billion. The company is well-positioned for future growth due to the increasing importance of pharmacy automation and the strategic relevance of its solutions.
Total revenues for the fourth quarter of 2020 were $249.2 million, up $0.9 million from the fourth quarter of 2019.
Fourth quarter 2020 GAAP net income was $16.4 million, or $0.37 per diluted share, compared to $22.1 million, or $0.51 per diluted share, for the fourth quarter of 2019.
Non-GAAP net income for the fourth quarter of 2020 was $40.2 million, or $0.91 per diluted share, compared to $33.5 million, or $0.77 per diluted share, for the fourth quarter of 2019.
Ended the year with record product bookings of more than $1 billion.
For the first quarter of 2021, the Company expects total revenues to be between $243 million and $248 million and non-GAAP earnings to be between $0.64 and $0.69 per share. For the full year 2021, the Company expects total revenues to be between $1.085 billion and $1.105 billion and non-GAAP earnings to be between $3.40 and $3.60 per share.
Analyze how earnings announcements historically affect stock price performance